Consolidated Net Income/Loss: A company's total income or loss before preferred stock dividends.
Reviva Pharmaceuticals Holdings, Inc. (RVPH) had Consolidated Net Income/Loss of $-39.26M for the most recently reported fiscal year, ending 2023-12-31.
Income Statement Financials | |
-- |
|
$-39.26M |
|
-- |
|
-- |
|
$39.50M |
|
$-39.50M |
|
$0.26M |
|
$-39.24M |
|
$-39.24M |
|
$-39.26M |
|
$-39.26M |
|
Consolidated Net Income/Loss |
$-39.26M |
$-39.26M |
|
$-39.50M |
|
$-39.50M |
|
23.80M |
|
23.80M |
|
$-1.65 |
|
$-1.65 |
|
Balance Sheet Financials | |
$23.70M |
|
-- |
|
-- |
|
$23.70M |
|
$17.18M |
|
-- |
|
$0.81M |
|
$17.98M |
|
$5.72M |
|
$5.72M |
|
$5.72M |
|
27.92M |
|
Cash Flow Statement Financials | |
$-28.32M |
|
-- |
|
$33.17M |
|
$18.52M |
|
$23.37M |
|
$4.85M |
|
$3.41M |
|
-- |
|
-- |
|
Fundamental Metrics & Ratios | |
1.38 |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
$-28.32M |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-- |
|
-686.53% |
|
-686.53% |
|
-165.65% |
|
-686.53% |
|
$0.20 |
|
$-1.19 |
|
$-1.19 |